To understand the specific contribution of inhibiting SHP2 in the cancer cells to anti-tumor immunity in vivo, we knocked out SHP2 in 4T1 cells by direct electroporation of CAS9 protein and sgRNA targeting Ptpn11 into 4T1 cells and established syngeneic model with 4T1-CAS9-sgPtpn11 cell pool which showed substantial knockout efficiency (Supplementary Fig. 9a). Here, PTPN11 is linked to neoplasm.